Our Participating Medicines
The Genentech medicines supported by the Genentech Patient Foundation are:
- Actemra® (tocilizumab)*
- Activase® (alteplase)
- Alecensa® (alectinib)
- Avastin® (bevacizumab)
- Cathflo Activase® (alteplase)
- COLUMVI™ (glofitamab-gxbm)
- Cotellic® (cobimetinib)*
- Enspryng™ (satralizumab-mwge)
- Erivedge® (vismodegib)
- Evrysdi™ (risdiplam)
- Gazyva® (obinutuzumab)
- Hemlibra® (emicizumab-kxwh)
- Herceptin® (trastuzumab)
- Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk)
- ITOVEBI™ (Inavolisib)
- Kadcyla® (ado-trastuzumab emtansine)
- Lucentis™ (ranibizumab injection)
- LUNSUMIO™ (mosunetuzumab-axgb)
- OCREVUS® (ocrelizumab)
- OCREVUS ZUNOVO™️ (ocrelizumab and hyaluronidase-ocsq)
- Perjeta® (pertuzumab)
- Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
- PiaSky™ (crovalimab-akkz)
- Polivy™ (polatuzumab vedotin-piiq)
- Pulmozyme® (dornase alfa)
- Rituxan® (rituximab)
- Rituxan Hycela™ (rituximab and hyaluronidase human)
- Rozlytrek™ (entrectinib)
- Susvimo™ (ranibizumab injection)
- TECENTRIQ® (atezolizumab)
- TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)
- TNKase® (tenecteplase)
- Vabysmo™ (faricimab)
- Venclexta® (venetoclax)
- Xolair® (omalizumab)
- Zelboraf® (vemurafenib)*
* The Genentech Patient Foundation has made the decision to stop accepting new enrollments for patients prescribed Actemra, Cotellic and Zelboraf effective January 1, 2027, and discontinue all Foundation support for these medications on December 31, 2027.
New enrollments will be accepted through December 31, 2026. For patients who remain eligible, the last day to request an upfront shipment will be December 22, 2027. All product replacement requests must be received by January 31, 2028 for any dates of service in 2027. Any missing information or documentation for incomplete enrollments or annual reverifications must be received by December 31, 2026. The Foundation will not re-open service requests after this deadline.
If you have been prescribed a participating medicine, you may qualify for support from the Genentech Patient Foundation. View the 'See If You Qualify' page to determine eligibility.
Support for Genentech medicines not listed above:
If you do not see your medicine listed, please contact our Patient Resource Center at 1 (877) GENENTECH (436-3683) for more information.